

# SAHA Patient: IV vs ORAL (200 mg/dose)

Patient #

1-OS-200

Week 1

Week 2

IV

ORAL

Marker

+

-

Pre

Post

Pre

Post-2hrs


Post-4hrs

$\alpha$ -AcH4

Coomassie blue

FIG. 1

**Protocol 01-021 (ORAL SAHA) ARM A: SOLID  
TUMOR PATIENTS Cohort I (200 mg/dose)**



**FIG. 2**

# SAHA Patients: ORAL /Cohort I (200 mg/dose)




FIG 3

**Protocol 01-021 (ORAL SAHA)**  
**ARM A: SOLID TUMOR PATIENTS**  
**Cohort I (200 mg/dose)**






FIG. 4

**Protocol 01-021 (ORAL SAHA)**  
**ARM A: SOLID TUMOR PATIENTS**  
**Cohort IIa (400 mg/dose)**  
**7-OS-400                      8-OS-400**



12/19/01

**9-OS-400**



12/27/01

FIG. 5

# SAHA Patients: ORAL/Cohort II (400 mg/dose)




FIG. 6

**Protocol 01-021 (ORAL SAHA )**  
**ARM A: SOLID TUMOR PATIENTS**  
**Cohort IIa (400 mg/dose)**




FIG. 7

# SAHA Patients. ORAL/Cohort II (400 mg/dose)





FIG. 8



# Oral 200 mg vs. 400 mg (Fasting)

Oral dose on Cycle 1 Day 8




Figure 9A

# Oral 200 mg vs. 400 mg (no-fasting)

Oral Dose on Cycle 1 Day 9




Figure 9B

# IV 200 mg vs. 400 mg

IV Dose on Cycle 1 Day 1





Figure 9C

# Apparent Half-life of the Oral Dose


---



3/4/2003

Figure 10

# AUC of the Oral Dose



■ =200 mg group (n=3-5); □ =400 mg group (n=5-10)

3/4/2003

Figure 11

# Bioavailability





Figure 12

# CTCL Patient 001 (MD Anderson)

---

**Baseline**



**After 1 week of SAHA**




FIG. 13A

# CTCL Patient 001 (MD Anderson)

---

Baseline



After 1 Week of SAHA




FIG. 13B

ATON  
P H A R M A


CONFIDENTIAL



# CTCL Patient 008 (MD Anderson)

---

**Baseline**



**After 8 weeks of SAHA**




FIG. 13C


**ATON**  
P H A R M A

CONFIDENTIAL

# CTCL Patient 008 (MD Anderson)

---

**Baseline**



**After 8 weeks of SAHA**




FIG. 13D


CONFIDENTIAL

ATON  
PHARMA

# Metastatic Laryngeal Cancer

---

Pre-treatment



After 8 weeks of  
treatment




FIG. 14

CONFIDENTIAL

ATON  
PHARMA